The Pre-Clinical Stage Deals and Alliances of 2014 report provides comprehensive understanding and unprecedented access to the partnering deals and agreements entered into by the worlds leading healthcare companies during 2014.
Using these reports, dealmakers will effectively and efficiently gain insight into the partnering activities of the past year. The report series allows you to view all the partnering and alliances deals announced worldwide.
The initial chapters of this report provide an orientation of 2014’s dealmaking and business activities.
Chapter 1 provides an overview of the trends in dealmaking during 2014 covering trends by deal type, stage of development, technology type and therapeutic indication.
Chapter 2 provides a review of the leading deals during 2014. Deals are listed by headline value, signed by bigpharma and bigbiotech, and most active bigpharma. Where the deal has an agreement contract published at the SEC a link provides online access to the contract.
Chapter 3 provides a comprehensive listing of the top 50 bigpharma companies with a brief summary followed by a comprehensive listing of 2013 deals, as well as contract documents available in the public domain. Each deal title links via Weblink to an online version of the deal record and where available, the contract document, providing easy access to each contract document on demand.
Chapter 4 provides a comprehensive directory of all partnering deals announced during 2014.
The chapter is organized by company A-Z, stage of development at signing, deal type (collaborative R&D, co-promotion, licensing etc), therapy area and technology type. Each deal title links via Weblink to an online version of the deal record and where available, the contract document, providing easy access to each contract document on demand.
The report series also includes numerous tables and figures that illustrate the trends and activities in bigpharma partnering and dealmaking during 2014.
In conclusion, this report provides everything a prospective dealmaker needs to know about partnering in the research, development and commercialization of technologies and products during 2014.
Table Of Contents
Pre-Clinical Stage Deals and Alliances of 2014 Executive Summary
Chapter 1 - Trends in dealmaking during 2014
1.1 Introduction 1.2. Partnering by deal type 1.3. Partnering by industry sector 1.4. Partnering by technology type 1.5. Partnering by therapy area
Chapter 2 - Average financial deal terms
2.1 Stage partnering with headline values 2.2 Stage partnering with upfront payments 2.3 Stage partnering with milestone payments 2.4 Stage partnering with royalty rates
Chapter 3 - Leading stage partnering deals during 2014
3.1. Introduction 3.2. Most active dealmakers 3.3. Top deals by value during 2014 3.4. Big pharma dealmaking activity 3.5. Big biotech dealmaking activity
Chapter 4 - Partnering deals directory 2014
4.1. Introduction 4.2. Company A-Z 4.3. By deal type 4.4. By technology type 4.5. By therapy area
About Wildwood Ventures Current Partnering Current Agreements
Table of figures Figure 1: Stage partnering by deal type during 2014 Figure 2: Stage partnering by industry sector during 2014 Figure 3: Stage partnering by technology type during 2014 Figure 4: Stage partnering by therapy area during 2014 Figure 5: Stage deals with a headline value Figure 6: Stage deal headline value distribution, US$million Figure 7: Stage deal upfront payment distribution, US$million Figure 8: Stage deals with milestone payments, US$million Figure 9: Stage deals with royalty rates, % Figure 10: Active dealmaking activity 2014 Figure 11: Top deals by value during 2014 Figure 12: Big pharma - top 50 - January to December 2014 Figure 13: Big pharma deal frequency - 2014 Figure 14: Big biotech - top 50 - January to December 2014 Figure 15: Big biotech deal frequency - 2014